(RFL) Rafael Holdings, Inc. Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RFL) Rafael Holdings, Inc. Complete Analysis Pack
Go Beyond the Preview—Access the Full Strategic Report
This Rafael Holdings, Inc. Porter's Five Forces Analysis helps you assess competitive pressure, industry attractiveness, and the forces shaping the company’s position. The page already shows a real preview of the report content, so you can review what’s included before buying the full ready-to-use version.
Suppliers Bargaining Power
Specialized biotech inputs
Supplier power is high because Rafael Holdings, Inc.’s pharmaceutical work depends on specialized API, assay reagents, and GMP sterile trial materials that are hard to replace. For CPI-613 and late-stage studies, a small pool of qualified vendors can push up costs and stretch lead times, especially when testing or manufacturing slots are tight. That makes any disruption in a single supplier chain a direct risk to timelines, margins, and trial execution.
CRO and trial site leverage
CROs and trial sites have strong leverage because they control patient recruitment and multi-center execution for oncology studies. In 2025, the global CRO market was about USD 60 billion, and experienced Phase III oncology sites are a scarce pool. For Rafael Holdings, Inc., that means higher fees, tighter schedules, and less negotiating power when trial providers are needed most.
Regulatory and quality providers
Rafael Holdings, Inc. relies on specialized quality, regulatory, and compliance providers to keep its drug candidate moving, and those services are hard to replace fast. For a small biotech with limited in-house scale, these vendors can hold stronger pricing and timing power, especially when filings, audits, or GMP reviews are on a tight clock. That makes supplier leverage moderate to high, because a delay in 1 critical workstream can slow the whole pipeline.
Property operations dependencies
Rafael Holdings, Inc.'s property operations rely on maintenance vendors, utilities, security, and parking support, but these suppliers are usually fragmented, so no single provider has strong pricing power. The real leverage comes from service quality: a missed repair or security lapse can hurt tenant satisfaction and occupancy. That keeps bargaining power moderate, not high.
- Fragmented vendors limit price control.
- Service quality affects occupancy.
- Key vendors still have some leverage.
Skilled scientific talent
Skilled scientific talent is a high-power supplier for Rafael Holdings, Inc. In pharma, experienced researchers and clinical specialists are scarce; the U.S. median pay for medical scientists was $100,890 in May 2024, and biotech turnover can stall trials and raise burn. When key scientists leave, timelines slip and development costs jump.
Scarce talent raises wage pressure.
Competitors bid for the same experts.
Staff loss can delay trials.
Delays lift R&D cash burn.
Rafael Holdings Faces High Supplier Power and Rising Execution Risk
Supplier power is high for Rafael Holdings, Inc. because CPI-613, oncology trials, and GMP work depend on scarce API, CRO, and clinical-site vendors. In 2025, the global CRO market was about USD 60 billion, and skilled medical scientists earned a median USD 100,890 in May 2024, showing tight labor and service supply. That raises costs, delays, and execution risk.
| Supplier | Power | Why it matters |
|---|---|---|
| CROs | High | Scarce Phase III oncology capacity |
| API and GMP vendors | High | Few qualified substitutes |
| Scientific talent | High | Median pay USD 100,890 |
What is included in the product
Detailed Word Document
Assesses Rafael Holdings, Inc.’s competitive pressures, supplier and buyer power, and entry threats shaping its market position.
Customizable Excel Spreadsheet
Quickly spot Rafael Holdings’ competitive pressures in one clear view—ideal for faster, smarter strategic decisions.
Reference Sources
Provides a clear source trail for Rafael Holdings, Inc., helping decision-makers verify key claims fast and trust the underlying analysis.
Customers Bargaining Power
Tenant negotiation leverage
Rafael Holdings, Inc. faces high tenant bargaining power in office leasing because weak demand and nearby alternatives let tenants press for lower rents, rent-free periods, and shorter commitments. U.S. office vacancy stayed near record highs in 2025, so landlords often had to give concessions to keep space filled. That matters most in a single key asset, where even a small occupancy drop can hit cash flow fast.
Patient and payer gatekeepers
For Rafael Holdings, Inc., the buyer is really physicians, hospitals, and payers, not just patients. In U.S. pharma, Medicare Part D and commercial formularies decide access, so reimbursement and treatment guidelines can swing uptake fast. Once a drug is commercialized, these gatekeepers hold strong leverage on price, volume, and share.
Limited near-term product choice
Before approval, CPI-613 has no normal consumer buying process, so customers cannot really push on price. Rafael Holdings still depends on trial sites, sponsors, and investigators to move the program forward; as of FY2025, it remained a clinical-stage asset, not a marketed drug. That keeps near-term buyer power low, but enrollment choices can still shape timelines and data quality.
Tenant concentration risk
Rafael Holdings, Inc. faces stronger customer power when a few office tenants drive most rent. In a market where U.S. office vacancy stayed near 20% in 2025, one vacancy or lease reset can hit segment cash flow fast. Long leases, staggered expiries, and retention work as the main shield against tenant pressure.
- Few tenants mean more bargaining power.
- One vacancy can move real estate income.
- Lease terms help protect pricing power.
Price sensitivity in both segments
Commercial tenants can push back hard because they can compare rent, free-rent periods, and site quality before renewing. In pharma, buyers and payers compare oncology benefit against other therapies and price, and many cancer drugs can run above $100,000 per patient each year, so value proof matters. That leaves Rafael Holdings exposed to heavy scrutiny on both lease economics and clinical value delivery.
- Tenants shop rent and incentives
- Payers judge drug value vs cost
- High prices raise buyer pressure
Rafael Faces Strong Customer Leverage in Office and Pharma
Rafael Holdings, Inc. faces strong customer power in office leasing because U.S. office vacancy stayed near 20% in 2025, so tenants can press for lower rent and richer concessions. In pharma, buyers and payers still have leverage because CPI-613 was clinical-stage in FY2025, so pricing power stays limited until approval and reimbursement are secured.
| Area | 2025/2026 fact | Customer power |
|---|---|---|
| Office | U.S. vacancy near 20% | High |
| Pharma | CPI-613 still clinical-stage | High after approval |
Preview the Actual Deliverable
Rafael Holdings, Inc. Porter's Five Forces Analysis
This preview shows the exact Rafael Holdings, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no samples, no placeholders. The document is fully formatted and ready for immediate use, giving you instant access to the same file shown here. What you see now is the final version, so you can buy with confidence knowing there are no surprises.
Rivalry Among Competitors
Intense oncology pipeline competition
CPI-613 faces fierce rivalry in pancreatic cancer, where 5-year relative survival is about 13%, and relapsed or refractory AML, where many late-stage and adjacent therapies are competing for the same patients. Dozens of biotech and pharma groups are chasing these markets, so trial readouts, speed, and physician trust drive share gains. In oncology, one weak dataset can quickly shift capital and prescriber attention.
Race for clinical milestones
Drug rivals race to post positive data, file first, and win approval first; in 2024, the FDA approved 50 novel drugs, showing how fast a single milestone can reshape the field. If a rival gets there first, investor attention and funding can shift away from Rafael Holdings, Inc.'s program. So timing and clean execution are major drivers of competitive rivalry.
Office market competition
Rafael Holdings, Inc. faces real office-landlord rivalry because tenants can still choose nearby buildings with lower rents, richer concessions, or newer lobbies. In a 2025 U.S. office market with vacancy still near 19%, leasing stayed competitive, so even a smaller portfolio must fight hard on price and quality. That keeps competitive rivalry meaningful versus larger landlords with deeper capital and bigger amenity budgets.
Capital market competition
Biotech firms compete for investor capital, analyst coverage, and partnership deals, and the biggest names usually get first pick. That matters for Rafael Holdings, Inc. because better-funded rivals can run more trials, add more assets, and keep extending pipelines, which raises the bar for a smaller holding company model.
- Capital flows favor larger biotech platforms.
- More cash means more trials and data.
- Smaller balance sheets face louder competition.
Mixed-business rivalry pressure
Rafael Holdings, Inc. faces rivalry from both life sciences developers and commercial property owners, and each market has its own pressure points. In life sciences, speed, funding, and clinical progress drive share; in property, occupancy, rent, and tenant retention matter. That split makes the rivalry moderate to high because both businesses need constant execution to stay competitive.
- Two rival pools, two different rules.
- Execution gaps can quickly erode share.
- Overall pressure stays moderate to high.
Rafael Faces Fierce Competition in Drugs and Offices
Competitive rivalry is high for Rafael Holdings, Inc. because CPI-613 competes in crowded oncology areas like pancreatic cancer, where 5-year relative survival is about 13%, and AML, where many late-stage rivals chase the same patients. Office assets also face strong price and occupancy pressure in a 2025 U.S. office market with vacancy near 19%. Bigger peers can outspend on trials and tenant perks.
| Driver | Data | Impact |
|---|---|---|
| Pancreatic cancer | 5-year survival ~13% | Heavy drug rivalry |
| U.S. office vacancy | Near 19% in 2025 | Lease competition |
| FDA novel drug approvals | 50 in 2024 | Faster race to market |
Substitutes Threaten
Existing cancer standards of care
For devimistat, Rafael Holdings, Inc. faces a high substitution threat because doctors already use standard chemotherapy and combo regimens like FOLFIRINOX and gemcitabine plus nab-paclitaxel. Those regimens set a strong benchmark, with median overall survival of about 11.1 months and 8.5 months in key pancreatic cancer trials. If current care looks good enough, physicians may not switch until devimistat proves clear clinical gain.
Alternative experimental therapies
Substitution risk is strong for Rafael Holdings, Inc. in oncology because physicians and payers can switch to other targeted drugs, immunotherapies, or combo regimens as soon as better data appears. In 2024, the U.S. FDA approved 50 novel drugs, and oncology kept taking a large share, showing how fast alternatives keep expanding. That pace can pull the same patients and revenue opportunity away from Rafael Holdings, Inc.'s pipeline.
Remote and hybrid work
Remote and hybrid work remain a real substitute for traditional offices. In 2025, U.S. office availability stayed above 20% in many major markets, showing how flexible work keeps pressure on demand. For Rafael Holdings, Inc.'s real estate division, tenants may lease less space or sign shorter deals, which can reduce income at its commercial office complex.
Flexible workspace options
Coworking, serviced offices, and short-term leases give tenants lower upfront cost and faster move-in than long-term leases, so they can pull demand away from Rafael Holdings, Inc. office space. In a weak office market, that flexibility can cap rent growth and hurt renewal rates, especially when tenants want to keep balance-sheet commitments light.
Lower commitment
Faster occupancy
Pressure on renewals
Alternative transportation and parking choices
Rafael Holdings, Inc. faces a real threat from rideshare, transit, cycling, and walkable access, because these options can replace paid parking when they are faster or cheaper. In dense U.S. cities, commute mode shifts can move parking demand fast; when utilization falls even 5% to 10%, parking income and the real estate value tied to it can weaken.
- Rideshare cuts parking need.
- Transit lowers daily car use.
- Bike and walk access divert commuters.
- Lower utilization hurts asset value.
High Substitute Risk Pressures Rafael Holdings Across Its Core Markets
Rafael Holdings, Inc. faces high substitute risk in devimistat because standard pancreatic cancer regimens like FOLFIRINOX still anchor care, with median overall survival near 11.1 months in key trials. In offices, remote work and coworking keep pressure on demand as U.S. office vacancy stayed above 20% in many markets in 2025. Parking also faces substitutes from transit and rideshare, which can cut utilization.
| Area | Substitute | Latest signal |
|---|---|---|
| Oncology | Standard chemo | 11.1 months OS |
| Office | Remote/coworking | Vacancy >20% |
| Parking | Transit/rideshare | Lower utilization |
Entrants Threaten
High biotech entry barriers
Late-stage oncology drug development is capital intensive and slow: a single Phase 3 trial can cost tens of millions, and full development often takes 10-15 years before any revenue. New entrants need deep scientific expertise, trial sites, and regulatory teams, while only about 10% of drug candidates reach approval. That makes direct entry into Rafael Holdings, Inc.'s niche hard.
Regulatory and clinical hurdles
Regulatory and clinical hurdles make new entry hard in Rafael Holdings, Inc.'s space. The FDA often requires multi-phase trials, with Phase 3 studies commonly enrolling hundreds to thousands of patients, plus ongoing safety monitoring and strict endpoint design. That drives up cost and failure risk, and credible clinical data remains a major barrier to casual entrants.
Capital intensive real estate entry
Commercial office entry is capital heavy: U.S. office loans are large, with the 10-year Treasury near 4% in 2025 and bank lending still selective, so new buyers need deep equity plus strong financing. Developers also face leasing, property ops, and tenant retention costs before cash flow turns steady. That makes easy entry into Rafael Holdings, Inc.'s real estate segment unlikely.
Location and asset quality advantages
Rafael Holdings, Inc. benefits from an established office complex with parking and a long operating history, which is hard for a new entrant to copy fast. A rival would need a similar location, tenant base, and built-in credibility, plus years to fill space and prove performance. That lowers the threat of new real estate entrants and gives Rafael Holdings, Inc. a real moat.
- Location is hard to replicate.
- Parking adds tenant value.
- History supports leasing trust.
- New entrants face long setup times.
Moderate local entry risk
Entry risk is uneven for Rafael Holdings, Inc. Biotech is hard to break into because drug development needs heavy capital, long timelines, and regulatory approval, while local real estate can still draw smaller owners with less money and no FDA-style gatekeeping. That keeps the threat of new entrants low to moderate, not severe.
Biotech barriers stay high.
Local real estate barriers are lower.
Entry pressure is mixed by segment.
Low Entry Threats Protect Rafael Holdings
Threat of new entrants for Rafael Holdings, Inc. stays low in biotech and moderate in real estate. Drug development can take 10-15 years, with only about 10% of candidates approved, so capital and regulatory barriers are high. Office entry is easier, but scarce financing and the need for prime assets still limit fast rivals.
| Segment | Barrier | Key fact |
|---|---|---|
| Biotech | High | 10-15 years; ~10% approval |
| Real estate | Moderate | 10-year Treasury near 4% in 2025 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.